CD134 as target for specific drug delivery to auto-aggressive CD4+T cells in adjuvant arthritis

Table 1 Anti-CD134 5'-fluoro-2'-deoxyuridine dipalmitate liposomes inhibit the proliferation of CD134⁺ T cells in vitro

Drug	Drug carrier	Targeting moiety	Inhibition of proliferation (%)
None	None	None	0.0 ± 8.2
FUdR	None	Anti-CD134	8.9 ± 8.7
FUdR-dP	Liposomes	None	6.3 ± 0.7
None	Liposomes	Anti-CD134	0.6 ± 1.1
FUdR-dP	Liposomes	Anti-CD134	31.0 ± 2.3*

Con A-activated CD134⁺ T cells of clone A2b were incubated for 30 min without ('none' under the heading 'drug') or with either free 5'-fluoro-2'-deoxyuridine (FUdR), 5'-fluoro-2'-deoxyuridine dipalmitate (FUdR-dP) liposomes, anti-CD134 liposomes, or anti-CD134-FUdR-dP liposomes. To each well was added 100 nM FUdR or 1 nmol of liposomal lipid (for FUdR-dP liposomes this equals 100 nM FUdR). Subsequently, cells were washed and cultured for 48 hours, followed by [³H]thymidine incorporation as a measure of proliferation. Results are expressed as the mean percentage of inhibition of proliferation relative to the incubation without liposomes (defined as 0%; mean [³H]thymidine incorporation of 53,330 c.p.m.). Results in the last column are means ± SEM. One representative experiment of three is shown. *P < 0.001 compared with incubation without liposomes.

ISSN: 1478-6362